Nuevolution is a Copenhagen-based biopharmaceutical company. Its patent protected Chemetics drug discovery platform enables the selection of drugs to an array of tough-to-drug disease targets. To date it has entered into 17 agreements with major pharmaceutical companies.
More Nuevolution content >Investment summary
Amgen has announced a recommended cash offer for Nuevolution’s shares of SEK32.50/share, valuing the company at approximately SEK1,610m (US$167m). The offer represents a 169% premium to the closing price (SEK12.10) on 21 May (the day before the announcement) and a 69% premium to the highest trading price (SEK19.26) over the 52-week period (before 21 May 2019). The offer has been accepted by 97.6% shareholders and Amgen has announced that conditions for completion of the offer have either been satisfied or waived, and declares that it is completing the offer. The settlement of the offer was completed on 15 July. Nuevolution has applied to Nasdaq Stockholm for delisting. As of 31 March 2019, Nuevolution had net cash of SEK86m.
Y/E Dec |
Revenue (SEKm) |
EBITDA (SEKm) |
PBT (SEKm) |
EPS (öre) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 12.2 | N/A | (123.8) | (274.3) | N/A | N/A |
| 2018A | 11.0 | N/A | (107.3) | (217.3) | N/A | N/A |
| 2019E | 202.4 | N/A | 87.2 | 114.6 | 28.3 | 30.1 |
| 2020E | 336.6 | N/A | 220.9 | 290.1 | 11.2 | 11.9 |
Industry outlook
Significant promise is seen in DNA-encoded libraries as a result of the potential to rapidly develop small molecule drugs to ‘tough-to-drug’ targets. We continue to see major investment in the space from an array of companies, notably GSK, Roche and Novartis.
Last updated on 26/07/2019Content on Nuevolution
Sector |
|---|
|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (SEKm) | 163.5 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Alex Gouliaev | CEO |
| Johnny Stilou | CFO |
| Thomas Franch | Chief Scientific Officer |
| Ton Berkien | Chief Business Officer |
You may also be interested in…
- Abliva
- AlzeCure Pharma
- ASIT biotech
- Basilea Pharmaceutica
- BerGenBio
- Cantargia
- Carmat
- Deinove
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- IRLAB Therapeutics
- Kiadis Pharma
- MagForce
- Medigene
- MOLOGEN
- Newron Pharmaceuticals
- Nicox
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Pharnext
- Photocure
- Pixium Vision
- Polyphor
- Probiodrug
- RhoVac
- Ryvu Therapeutics
- Scandion Oncology
- Sequana Medical
- Targovax
- Transgene
- TxCell
- Ultimovacs
- Vivesto
- Xbrane Biopharma